Please see our disclaimer about how to use this information and also our copyright restrictions if you want to repurpose or are thinking of copying this information.
MLD is short for metachromatic leukodystrophy. Translated from doctor talk MLD means: meta - change, chromatic - color, leuko - white matter, dystrophy - degeneration. MLD's name therefore comes from degeneration in the white matter of the brain and Central Nervous System (CNS) which has a color on staining that should not be there. Staining was how the disease was observed before the advent of the MRI.
Biochemistry Basically people who are affected by MLD lack an enzyme in their blood called Arylsulfatase-A, (ARSA). Without this enzyme, sulfatides are NOT broken down and instead build-up in the white matter of the brain and CNS causing destruction of the myelin sheath, or demyelination. Without an intact myelin sheath there is a breakdown in communication between the nerves and the brain. This loss of or miscommunication accounts for the loss of acquired functions, paralysis, blindness, seizures and eventual death seen in MLD.
Types of MLD Generally, there are considered to be three main types of MLD that have different ages of onset: late-infantile, juvenile, and adult. The late-infantile form of MLD is the most commonly observed form of MLD. The most common gene mutations have been identified for both the late-infantile and the adult onsets, however, there are many other less common mutations.
MLD is not contagious and can not be passed to others through any sort of contact - it is a genetic condition.
Therapies & Research At this time there is no cure for MLD. The only treatment is bone marrow transplant (BMT) or stem cell transplant (SCT), and they are most effective in slowing the disease in people who are not showing any significant symptoms of MLD (pre-symptomatic). Research is making strides towards in the areas of improved bone marrow transplants, enzyme replacement therapy, gene therapy, and cell line studies.
Genetics & Frequency MLD is an autosomal recessive genetic defect. Translated this means both males and females carry the gene and both parents need to carry the defective gene in order to have an affected child. It is estimated the carrier defect occurs in in the general population at 1 in every 100 people and the affected birth rate is 1:40,000 – thus MLD gets its designation of being a rare disease.
Our experience, however, is the most frequent form of MLD, infantile onset, is often not diagnosed properly prior to death of the patient and later onsets of MLD are often misdiagnosed as ADHD, ADD, or psychiatric conditions and hence the frequency might be higher than reported.
We estimate that approximately 1,900 new late infantile babies are born each year (60 in the US and 170 in Europe) and there are approximately 41,000 people alive at any given time with all forms of MLD worldwide.
History The first report of MLD was in 1933 and is commonly credited to Dr. Joseph Godwin Greenfield,(1884-1958) a professor of pathology and clinical medicine at what is now the National Hospital for Neurology & Neurosurgery in Edinburgh, London UK – (same campus as what is now the Great Ormond Street hospital for Children. MLD was first called Greenfield's disease. The first published reports of MLD appeared in the early 1960's with the first experimental bone marrow transplants treatments in the early 1980's.*